INS and type 2 diabetes mellitus: 2,4-dioxo-N-(4-(pyridin-3-yloxy) phenyl)-1,2,3,4-tetrahydroquinazoline-6-sulfonamide, a Sirt6 inhibitor, improved glucose tolerance in mice, and reduced insulin, triglycerides, and cholesterol levels indicating that a Sirt6 inhibitor could improve glycemic control in T2DM (Sociali et al., 2017; Khan R. I. et al., 2018).